Parechovirus

An important emerging infection in young infants

Philip N. Britton, Cheryl A. Jones, Kristine Macartney, Allen C. Cheng

Research output: Contribution to journalReview ArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Epidemics of human parechovirus (HPeV) causing disease in young children have occurred every 2 years in Australia since 2013. HPeV genotype 3 caused the epidemic from late 2017 to early 2018. Most HPeV infections cause no or mild symptoms including gastroenteritis or influenza-like illness. Characteristically, young infants present with fever, irritability and on occasions a diffuse rash (“red, hot and angry” babies). Severe disease can manifest as meningoencephalitis, seizures or sepsis-like presentations (including septic shock), or less common presentations including signs of surgical abdomen. Testing for HPeV by specific molecular tests is indicated in children younger than 6 months of age with characteristic presentations without another confirmed diagnosis including febrile illnesses with other suggestive features (eg, rash, seizures), sepsis syndromes (including shock), and suspected meningoencephalitis (which may be detected by magnetic resonance imaging only). There are no effective antiviral therapies. Treatment is primarily supportive, including management of complications. Some infants with severe HPeV infection may have adverse neurodevelopment. Follow-up by a paediatrician is recommended.

Original languageEnglish
Pages (from-to)365-369
Number of pages5
JournalMedical Journal of Australia
Volume208
Issue number8
DOIs
Publication statusPublished - 7 May 2018

Cite this

Britton, Philip N. ; Jones, Cheryl A. ; Macartney, Kristine ; Cheng, Allen C. / Parechovirus : An important emerging infection in young infants. In: Medical Journal of Australia. 2018 ; Vol. 208, No. 8. pp. 365-369.
@article{a9269665e1d04e18b0ed0cabf0983859,
title = "Parechovirus: An important emerging infection in young infants",
abstract = "Epidemics of human parechovirus (HPeV) causing disease in young children have occurred every 2 years in Australia since 2013. HPeV genotype 3 caused the epidemic from late 2017 to early 2018. Most HPeV infections cause no or mild symptoms including gastroenteritis or influenza-like illness. Characteristically, young infants present with fever, irritability and on occasions a diffuse rash (“red, hot and angry” babies). Severe disease can manifest as meningoencephalitis, seizures or sepsis-like presentations (including septic shock), or less common presentations including signs of surgical abdomen. Testing for HPeV by specific molecular tests is indicated in children younger than 6 months of age with characteristic presentations without another confirmed diagnosis including febrile illnesses with other suggestive features (eg, rash, seizures), sepsis syndromes (including shock), and suspected meningoencephalitis (which may be detected by magnetic resonance imaging only). There are no effective antiviral therapies. Treatment is primarily supportive, including management of complications. Some infants with severe HPeV infection may have adverse neurodevelopment. Follow-up by a paediatrician is recommended.",
author = "Britton, {Philip N.} and Jones, {Cheryl A.} and Kristine Macartney and Cheng, {Allen C.}",
year = "2018",
month = "5",
day = "7",
doi = "10.5694/mja18.00149",
language = "English",
volume = "208",
pages = "365--369",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "AMPCo",
number = "8",

}

Parechovirus : An important emerging infection in young infants. / Britton, Philip N.; Jones, Cheryl A.; Macartney, Kristine; Cheng, Allen C.

In: Medical Journal of Australia, Vol. 208, No. 8, 07.05.2018, p. 365-369.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Parechovirus

T2 - An important emerging infection in young infants

AU - Britton, Philip N.

AU - Jones, Cheryl A.

AU - Macartney, Kristine

AU - Cheng, Allen C.

PY - 2018/5/7

Y1 - 2018/5/7

N2 - Epidemics of human parechovirus (HPeV) causing disease in young children have occurred every 2 years in Australia since 2013. HPeV genotype 3 caused the epidemic from late 2017 to early 2018. Most HPeV infections cause no or mild symptoms including gastroenteritis or influenza-like illness. Characteristically, young infants present with fever, irritability and on occasions a diffuse rash (“red, hot and angry” babies). Severe disease can manifest as meningoencephalitis, seizures or sepsis-like presentations (including septic shock), or less common presentations including signs of surgical abdomen. Testing for HPeV by specific molecular tests is indicated in children younger than 6 months of age with characteristic presentations without another confirmed diagnosis including febrile illnesses with other suggestive features (eg, rash, seizures), sepsis syndromes (including shock), and suspected meningoencephalitis (which may be detected by magnetic resonance imaging only). There are no effective antiviral therapies. Treatment is primarily supportive, including management of complications. Some infants with severe HPeV infection may have adverse neurodevelopment. Follow-up by a paediatrician is recommended.

AB - Epidemics of human parechovirus (HPeV) causing disease in young children have occurred every 2 years in Australia since 2013. HPeV genotype 3 caused the epidemic from late 2017 to early 2018. Most HPeV infections cause no or mild symptoms including gastroenteritis or influenza-like illness. Characteristically, young infants present with fever, irritability and on occasions a diffuse rash (“red, hot and angry” babies). Severe disease can manifest as meningoencephalitis, seizures or sepsis-like presentations (including septic shock), or less common presentations including signs of surgical abdomen. Testing for HPeV by specific molecular tests is indicated in children younger than 6 months of age with characteristic presentations without another confirmed diagnosis including febrile illnesses with other suggestive features (eg, rash, seizures), sepsis syndromes (including shock), and suspected meningoencephalitis (which may be detected by magnetic resonance imaging only). There are no effective antiviral therapies. Treatment is primarily supportive, including management of complications. Some infants with severe HPeV infection may have adverse neurodevelopment. Follow-up by a paediatrician is recommended.

UR - http://www.scopus.com/inward/record.url?scp=85046891897&partnerID=8YFLogxK

U2 - 10.5694/mja18.00149

DO - 10.5694/mja18.00149

M3 - Review Article

VL - 208

SP - 365

EP - 369

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - 8

ER -